Correlation of Serum Estradiol with Bone Mineral Density and Bone Metabolism in Patients of Postmenopausal Type 2 Diabetes Mellitus Complicated with Osteoporosis

Abstract

Type 2 diabetes mellitus (T2DM) complicated with osteoporosis, is a systemic metabolic disease that affects postmenopausal women. This disease is closely related to the lack of estrogen. This study aims to demonstrate the correlation between serum estradiol (E2) levels and osteoporosis, bone mineral density, and bone metabolism indicators in postmenopausal women with T2DM complicated with osteoporosis (T2DM-OP). 130 postmenopausal women with T2DM were divided into the T2DM group (n=62) and the T2DM-OP group (n=68) according to bone mineral density (BMD). In addition, 80 postmenopausal women with average blood glucose and bone density were selected as the healthy control group. We compare the serum levels of E2, bone metabolism indicators, and biochemistry indexes among the three groups of participants. Compared with the healthy control and T2DM groups, the BMD and serum level of E2 in T2DM-OP patients were significantly decreased, while the serum levels of bone alkaline phosphatase, type I procollagen amino-terminal propeptide, osteocalcin, and β-collagen C-terminal collagen cross-links were significantly increased. The serum levels of E2 in the postmenopausal T2DM-OP patients are positively correlated with BMD and negatively correlated with bone resorption indicators.

bone metabolism - bone mineral density - estradiol, postmenopausal type 2 diabetes mellitus - osteoporosis

Publication History

Received: 16 February 2022

Accepted after revision: 16 May 2022

Article published online:
14 July 2022

• References

• 1 Zamani M, Zamani V, Heidari B. et al. Prevalence of osteoporosis with the World Health Organization diagnostic criteria in the Eastern Mediterranean Region: a systematic review and meta-analysis. Arch Osteoporos 2018; 13: 129
• 2 Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 2014; 142: 155-170
• 3 Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2016; 374: 254-262
• 4 Svedbom A, Hernlund E, Ivergard M. et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013; 8: 137
• 5 Lu YC, Lin YC, Lin YK. et al. Prevalence of osteoporosis and low bone mass in older Chinese population based on bone mineral density at multiple skeletal sites. Sci Rep 2016; 6: 25206
• 6 Kung AW, Fan T, Xu L. et al. Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study. BMC Womens Health 2013; 13: 7
• 7 Fu C, Shi R.. Osteoclast biology in bone resorption: a review. STEMedicine 2020; 1: e57
• 8 de L, van der Klift M, de Laet CE. et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 2005; 16: 1713-1720
• 9 Xia JW, Tan SJ, Zhang XL. et al. Correlation of serum testosterone with insulin resistance in elderly male type 2 diabetes mellitus patients with osteoporosis. J Diabetes Investig 2015; 6: 548-552
• 10 Ardawi MS, Rouzi AA, Al-Sibiani SA. et al. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study. J Bone Miner Res 2012; 27: 2592-2602
• 11 Chung YS, Chung DJ, Kang MI. et al. Vitamin D repletion in Korean postmenopausal women with osteoporosis. Yonsei Med J 2016; 57: 923-927
• 12 Abdi H, Hosseinpanah F, Azizi F. et al. Screening for dysglycemia: a comment on classification and diagnosis of diabetes in American diabetes association standards of medical care in diabetes-2016. Arch Iran Med 2017; 20: 389
• 13 Kalimeri M, Leek F, Wang NX. et al. Folate and vitamin B-12 status is associated with bone mineral density and hip strength of postmenopausal Chinese-Singaporean women. JBMR Plus 2020; 4: e10399
• 14 Farr JN, Khosla S. Determinants of bone strength and quality in diabetes mellitus in humans. Bone 2016; 82: 28-34
• 15 Park SY, Ahn SH, Yoo JI. et al. Clinical application of bone turnover markers in osteoporosis in Korea. J Bone Metab 2019; 26: 19-24
• 16 de Waard EA, van Geel TA, Savelberg HH. et al. Increased fracture risk in patients with type 2 diabetes mellitus: an overview of the underlying mechanisms and the usefulness of imaging modalities and fracture risk assessment tools. Maturitas 2014; 79: 265-274
• 17 Poiana C, Capatina C.. Fracture risk assessment in patients with diabetes mellitus. J Clin Densitom 2017; 20: 432-443
• 18 Napoli N, Chandran M, Pierroz DD. et al. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol 2017; 13: 208-219
• 19 Miyake H, Kanazawa I, Sugimoto T. Association of bone mineral density, bone turnover markers, and vertebral fractures with all-cause mortality in type 2 diabetes mellitus. Calcif Tissue Int 2018; 102: 1-13
• 20 Jang M, Kim H, Lea S. et al. Effect of duration of diabetes on bone mineral density: a population study on East Asian males. BMC Endocr Disord 2018; 18: 61–70
• 21 Leidig-Bruckner G, Grobholz S, Bruckner T. et al. Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. BMC Endocr Disord 2014; 14: 33
• 22 Ma L, Oei L, Jiang L. et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol 2012; 27: 319-332
• 23 Afshinnia F, Chacko S, Zahedi T. Association of lower serum cholesterol levels with higher risk of osteoporosis in type 2 diabetes. Endocr Pract 2007; 13: 620-628
• 24 Ettinger MP. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Arch Intern Med 2003; 163: 2237-2246
• 25 Moberg L, Nilsson PM, Samsioe G. et al. Low androstenedione/sex hormone binding globulin ratio increases fracture risk in postmenopausal women. The women's health in the Lund area study. Maturitas 2013; 75: 270-275
• 26 Ran C, Xiaojuan X, Wenxue G. et al. Sexual dimorphism in the relation between sex hormones and osteoporosis in patients with type 2 diabetes mellitus. J Bone Miner Metab 2022; 40: 460-467
• 27 Kanda J, Furukawa M, Izumo N. et al. Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice. Drug Discov Ther 2020; 14: 218-225
• 28 Purnamasari D, Puspitasari MD, Setiyohadi B. et al. Low bone turnover in premenopausal women with type 2 diabetes mellitus as an early process of diabetes-associated bone alterations: a cross-sectional study. BMC Endocr Disord 2017; 17: 72
• 29 Picke AK, Campbell G, Napoli N. et al. Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. Endocr Connect 2019; 8: R55-R70
• 30 Szeliga A, Maciejewska-Jeske M, Meczekalski B.. Bone health and evaluation of bone mineral density in patients with premature ovarian insufficiency. Prz Menopauzalny 2018; 17: 112-116
• 31 Snyder PJ, Kopperdahl DL, Stephens-Shields AJ. et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med 2017; 177: 471-479
• 32 Han K, Yun YM, Moon SG. et al. Bone mineral density and serum 25-hydroxyvitamin D in subtypes of idiopathic benign paroxysmal positional vertigo. Am J Otolaryngol 2020; 41: 102313
• 33 Zhang B, Zhao W, Tu J. et al. The relationship between serum 25-hydroxyvitamin D concentration and type 2 diabetic peripheral neuropathy: A systematic review and a meta-analysis. Medicine (Baltimore) 2019; 98: e18118
• 34 Ouyang X, Ding Y, Yu L. et al. Comparison of the clinical effect of DHS and PFNA on senile osteoporotic fracture and their significance of changes in BALP expression level. J Musculoskelet Neuronal Interact 2020; 20: 556-562
• 35 Lertwanakarn T, Suntravat M, Sanchez EE. et al. Suppression of cardiomyocyte functions by beta-CTX isolated from the Thai king cobra (Ophiophagus hannah) venom via an alternative method. J Venom Anim Toxins Incl Trop Dis 2020; 26: e20200005
• 36 Bhattoa HP, Cavalier E, Eastell R. et al. Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and beta-CTX in blood. Clin Chim Acta 2021; 515: 16-20
• 37 Shetty S, Kapoor N, Bondu JD. et al. Bone turnover markers: Emerging tool in the management of osteoporosis. Indian J Endocrinol Metab 2016; 20: 846-852
• 38 Stern A, Laughlin GA, Bergstrom J. et al. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 2007; 156: 555-562
• 39 Fatchiyah F, Setiawan B, Sasase T. et al. The amelioration of T2DM rat femoral bone achieved by anti-osteoporosis of caprine CSN1S2 protein through bone morphogenetic protein signaling pathway. Acta Biochim Pol 2021; 68: 265-275
• 40 Wang X, Jiang L, Shao X. Association analysis of insulin resistance and osteoporosis risk in Chinese patients with T2DM. Ther Clin Risk Manag 2021; 17: 909-916